Amneal (AMRX) | Financial Analysis & Statements
Amneal Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
814.3M
Gross Profit
297.2M
36.50%
Operating Income
114.5M
14.06%
Net Income
49.6M
6.09%
EPS (Diluted)
$0.11
Balance Sheet Metrics
Total Assets
3.7B
Total Liabilities
3.7B
Shareholders Equity
-71.3M
Cash Flow Metrics
Operating Cash Flow
103.7M
Free Cash Flow
84.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Amneal Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.0B | 2.8B | 2.4B | 2.2B | 2.1B |
| Cost of Goods Sold | 1.9B | 1.8B | 1.6B | 1.4B | 1.3B |
| Gross Profit | 1.1B | 1.0B | 820.6M | 784.7M | 769.0M |
| Gross Margin % | 36.9% | 36.5% | 34.3% | 35.5% | 36.7% |
| Operating Expenses | |||||
| Research & Development | 193.8M | 196.6M | 167.8M | 200.0M | 209.6M |
| Selling, General & Administrative | 526.8M | 476.4M | 429.7M | 399.7M | 365.5M |
| Other Operating Expenses | -5.2M | - | -1.1M | -4.0M | - |
| Total Operating Expenses | 715.4M | 673.0M | 596.3M | 595.8M | 575.1M |
| Operating Income | 397.9M | 347.4M | 224.2M | 188.9M | 193.9M |
| Operating Margin % | 13.2% | 12.4% | 9.4% | 8.5% | 9.3% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 241.1M | 258.6M | 210.6M | 158.4M | 136.3M |
| Other Non-Operating Income | 13.8M | -143.9M | -13.1M | -278.4M | -26.2M |
| Pre-tax Income | 139.2M | -55.0M | -40.3M | -248.1M | 31.4M |
| Income Tax | 11.3M | 18.9M | 8.5M | 6.7M | 11.2M |
| Effective Tax Rate % | 8.1% | 0.0% | 0.0% | 0.0% | 35.7% |
| Net Income | 127.9M | -73.9M | -48.7M | -254.8M | 20.2M |
| Net Margin % | 4.2% | -2.6% | -2.0% | -11.5% | 1.0% |
| Key Metrics | |||||
| EBITDA | 606.6M | 595.4M | 418.0M | 446.6M | 442.6M |
| EPS (Basic) | $0.23 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
| EPS (Diluted) | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
| Basic Shares Outstanding | 313367000 | 308978000 | 176136000 | 150944000 | 148922000 |
| Diluted Shares Outstanding | 313367000 | 308978000 | 176136000 | 150944000 | 148922000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Amneal Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 282.0M | 110.6M | 91.5M | 26.0M | 247.8M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 895.1M | 775.7M | 613.7M | 741.8M | 662.6M |
| Inventory | 606.3M | 612.5M | 581.4M | 530.7M | 489.4M |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 1.9B | 1.6B | 1.4B | 1.4B | 1.5B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 107.4M | 98.8M | 102.6M | 119.5M | 124.8M |
| Goodwill | 1.8B | 1.9B | 2.1B | 2.3B | 2.4B |
| Intangible Assets | 563.5M | 732.4M | 890.4M | 1.1B | 1.2B |
| Long-term Investments | 5.8M | 35.9M | 37.1M | 85.6M | 0 |
| Other Non-Current Assets | 14.5M | 8.1M | 11.6M | 10.4M | 10.8M |
| Total Non-Current Assets | 1.8B | 1.9B | 2.1B | 2.4B | 2.4B |
| Total Assets | 3.7B | 3.5B | 3.5B | 3.8B | 3.9B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 254.7M | 258.7M | 143.6M | 166.0M | 131.1M |
| Short-term Debt | 21.6M | 340.3M | 227.6M | 104.6M | 46.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 43.3M | 31.8M | 77.0M | 107.5M | 58.0M |
| Total Current Liabilities | 881.6M | 1.1B | 846.6M | 752.8M | 677.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.7B | 2.3B | 2.5B | 2.7B | 2.8B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 92.7M | 94.1M | 8.2M | 70.2M | 2.7M |
| Total Non-Current Liabilities | 2.9B | 2.5B | 2.6B | 2.9B | 2.9B |
| Total Liabilities | 3.7B | 3.6B | 3.5B | 3.6B | 3.6B |
| Equity | |||||
| Common Stock | 3.1M | 3.1M | 3.1M | 3.0M | 3.0M |
| Retained Earnings | -535.0M | -607.1M | -490.2M | -406.2M | -276.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -71.3M | -109.5M | 20.0M | 184.0M | 367.0M |
| Key Metrics | |||||
| Total Debt | 2.7B | 2.6B | 2.8B | 2.8B | 2.9B |
| Working Capital | 1.0B | 458.0M | 531.3M | 659.0M | 842.9M |
Balance Sheet Composition
Amneal Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 127.9M | -73.9M | -48.7M | -254.8M | 20.2M |
| Depreciation & Amortization | 223.6M | 236.2M | 229.4M | 240.2M | 233.4M |
| Stock-Based Compensation | 32.0M | 27.8M | 26.8M | 31.8M | 28.4M |
| Working Capital Changes | -186.3M | -57.6M | -94.8M | -71.9M | -109.3M |
| Operating Cash Flow | 256.9M | 136.9M | 157.1M | -37.2M | 187.9M |
| Investing Activities | |||||
| Capital Expenditures | -96.7M | -60.3M | -46.8M | -48.8M | -50.9M |
| Acquisitions | 0 | 12.0M | 0 | -84.7M | -146.5M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -96.7M | -48.3M | -46.8M | -132.5M | -192.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 2.7B | 0 | 217.7M | 0 | 0 |
| Debt Repayment | -2.8B | -233.1M | -414.1M | -123.3M | -79.2M |
| Financing Cash Flow | -2.8B | -212.9M | -213.0M | -107.3M | -139.0M |
| Free Cash Flow | 225.6M | 220.1M | 276.4M | -25.5M | 189.2M |
| Net Change in Cash | -2.7B | -124.3M | -102.7M | -277.0M | -143.5M |
Cash Flow Trend
Amneal Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
63.23
Forward P/E
11.78
Price to Book
-57.42
Price to Sales
1.47
PEG Ratio
-0.30
Profitability Ratios
Profit Margin
2.39%
Operating Margin
14.06%
Return on Equity
-101.02%
Return on Assets
7.32%
Financial Health
Current Ratio
2.17
Debt to Equity
45,095.52
Beta
1.32
Per Share Data
EPS (TTM)
$0.22
Book Value per Share
$-0.23
Revenue per Share
$9.63
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AMRX | 4.2B | 63.23 | -57.42 | -101.02% | 2.39% | 45,095.52 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Alkermes plc | 5.6B | 23.71 | 3.09 | 14.72% | 16.37% | 3.85 |
| Lantheus Holdings | 5.4B | 24.30 | 4.91 | 21.45% | 15.15% | 57.19 |
| Indivior PLC | 4.0B | 20.22 | -42.07 | -212.12% | 16.95% | -3.55 |
Financial data is updated regularly. All figures are in the company's reporting currency.






